A novel approach for tumor sensitivity prediction and combination therapy design for targeted drugs

Drugs that target specific kinases are becoming common in cancer research. Cancer-related kinases are the paradigm of molecularly-targeted therapies, and a cornerstone of Personalized Cancer Therapy. Here, we present an approach to generate abstract circuit representations of cancer pathways from drug tumor sensitivity data of a cell line and utilize them to predict the sensitivities of a new drug given the kinase inhibitors of the drug and to design and measure the effectiveness of drug combination therapies.

[1]  Noriyuki Nakatsu,et al.  Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays , 2005, Molecular Cancer Therapeutics.

[2]  Julio Saez-Rodriguez,et al.  Identifying Drug Effects via Pathway Alterations using an Integer Linear Programming Optimization Formulation on Phosphoproteomic Data , 2009, PLoS Comput. Biol..

[3]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[4]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[5]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[6]  Mark R. Green,et al.  Targeting targeted therapy. , 2004, The New England journal of medicine.

[7]  Yusuke Nakamura,et al.  Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.

[8]  Douglas B. Kell,et al.  System Modeling in Cell Biology From Concepts to Nuts and Bolts , 2005 .

[9]  J. Sklar,et al.  Molecular Tumor Profiling for Prediction of Response to Anticancer Therapies , 2011, Cancer journal.

[10]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[11]  Laura Tolosi,et al.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.

[12]  B. Druker,et al.  Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.

[13]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  John F. Karpovich,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2008 .

[15]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[16]  B. Druker,et al.  Molecularly targeted therapy: have the floodgates opened? , 2004, The oncologist.

[17]  Vipul Periwal,et al.  System Modeling in Cellular Biology: From Concepts to Nuts and Bolts , 2006 .